It’s a good Monday for investors of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), Amicus Therapeutics, Inc. (NASDAQ:FOLD), and Oasis Petroleum Inc. (NYSE:OAS), as all three stocks have made significant jumps today. We’ll take a look at the reason why these stocks are being propelled higher and whether elite money managers think the gains are sustainable or not.
Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole. These small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Moreover, since the beginning of forward testing from August 2012, the strategy worked just as our research predicted, outperforming the market every year and returning 118% over the last 36 months, which is more than 60 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).
ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)’s shares are up by a staggering 105.69% after the firm announced that its preliminary data for CMX157, its lipid prodrug of tenofovir, has shown that the treatment is 60-fold more effective than Gilead Sciences, Inc. (NASDAQ:GILD)’s Viread (tenofovir disoproxil fumarate) based on in vitro studies targeting the hepatitis B virus (HBV). The significant difference in effectiveness points to a considerable increase in safety and reduction of side effects compared to Viread, the firm notes. ContraVir said that since the lipid-conjugate design of CMX157 differentiates the drug from Viread, they plan to file an investigational new drug application for CMX157 as a treatment for HBV before the year ends. The firm also announced that its Phase 2 study for the drug for treating hepatitis B will start in 2016. It should be noted, nonetheless, that none of the more than 700 investors we track reported owning shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by the end of the second quarter.